- The Risk Evaluation and Education for Alzheimer's Disease (REVEAL) Study is an ongoing series of multi-site randomized controlled trials that provide empirical data to address ethical, social and translational issues in genetic susceptibility testing for common diseases. Such work has become increasingly important given the expansion of genome-wide association studies identifying genetic risk factors for common diseases and corresponding efforts to commercialize genetic testing using these markers. Our paradigm for these trials is disclosure of Apolipoprotein E (APOE) genotype as part of risk assessment for Alzheimer's disease (AD) to unaffected individuals. In previous funding cycles we have enrolled 1000 participants in three separate trials, and our multi-disciplinary team has been highly productive in analyzing many aspects of the psychological impact and health behavior changes of receiving genetic risk information. We now propose the first translational genetics study to focus upon the situation where mild early symptoms of a disease (phenotype) and known genetic marker (genotype) information can be used together to produce more imminent risk projections. To do this, we will develop genotype specific risk curves for patients with Mild Cognitive Impairment, a condition where the APOE epsilon 4 allele is associated with more rapid progression to AD and differential response to certain pharmacological treatments. We will carry out a new randomized clinical trial to examine the impact of "imminent risk assessment" (i.e., risk of conversion to AD within 3 years) in these individuals and their care partners. We also propose to develop and validate a novel instrument, which we call the Capacity Assessment Tool for Genetic Testing, to reliably assess an individual's capacity to consent to genetic testing, which will be useful for clinicians and researchers working with neuropsychiatric diseases. Finally, we propose to systematically study the long-term psychological impact and health behavior changes in participants who learned their APOE genotype in earlier cycles of the REVEAL Study, some of whom were enrolled as early as 2000. These data will help inform policy and practice regarding the use of genetic risk information for common, complex diseases. Public Health Relevance: REVEAL IV Project Narrative: In this continuation of the REVEAL Study, we will conduct a new randomized clinical trial to determine the psychological and health behavior changes associated with disclosing APOE genotype and 3-year risk estimates to persons with mild memory problems. We will also create a new instrument that clinicians and researchers can use to reliably evaluate a patient's capacity to consent to genetic testing and examine long-term impact of genetic risk assessment by following REVEAL Study patients 2-10 years following disclosure.

Public Health Relevance

In this continuation of the REVEAL Study, we will conduct a new randomized clinical trial to determine the psychological and health behavior changes associated with disclosing APOE genotype and 3-year risk estimates to persons with mild memory problems. We will also create a new instrument that clinicians and researchers can use to reliably evaluate a patient's capacity to consent to genetic testing and examine long-term impact of genetic risk assessment by following REVEAL Study patients 2-10 years following disclosure.

Agency
National Institute of Health (NIH)
Institute
National Human Genome Research Institute (NHGRI)
Type
Research Project (R01)
Project #
5R01HG002213-12
Application #
8333459
Study Section
Ethical, Legal, and Social Implications of Human Genetics Study Section (ELS)
Program Officer
Mcewen, Jean
Project Start
1999-09-30
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2014-06-30
Support Year
12
Fiscal Year
2012
Total Cost
$584,295
Indirect Cost
$171,183
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Gross, Alden L; Sherva, Richard; Mukherjee, Shubhabrata et al. (2014) Calibrating longitudinal cognition in Alzheimer's disease across diverse test batteries and datasets. Neuroepidemiology 43:194-205
Shen, Li; Thompson, Paul M; Potkin, Steven G et al. (2014) Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers. Brain Imaging Behav 8:183-207
Sparks, Jeffrey A; Iversen, Maura D; Miller Kroouze, Rachel et al. (2014) Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) Family Study: rationale and design for a randomized controlled trial evaluating rheumatoid arthritis risk education to first-degree relatives. Contemp Clin Trials 39:145-57
Sharp, Aaron R; Ridge, Perry G; Bailey, Matthew H et al. (2014) Population substructure in Cache County, Utah: the Cache County study. BMC Bioinformatics 15 Suppl 7:S8
Lerner, Barbara; Roberts, J Scott; Shwartz, Michael et al. (2014) Distinct communication patterns during genetic counseling for late-onset Alzheimer's risk assessment. Patient Educ Couns 94:170-9
Roberts, J Scott; Dolinoy, Dana C; Tarini, Beth A (2014) Emerging issues in public health genomics. Annu Rev Genomics Hum Genet 15:461-80
Wang, Catharine; Gordon, Erynn S; Stack, Catharine B et al. (2014) A randomized trial of the clinical utility of genetic testing for obesity: design and implementation considerations. Clin Trials 11:102-13
Karlawish, Jason; Green, Robert C (2014) Minding the aging brain: are we ready for personalized medicine? Am J Psychiatry 171:137-9
Sherva, Richard; Tripodis, Yorghos; Bennett, David A et al. (2014) Genome-wide association study of the rate of cognitive decline in Alzheimer's disease. Alzheimers Dement 10:45-52
McGuire, Amy L; Joffe, Steven; Koenig, Barbara A et al. (2013) Point-counterpoint. Ethics and genomic incidental findings. Science 340:1047-8

Showing the most recent 10 out of 72 publications